Non-classical monocytes promote neurovascular repair in cerebral small vessel disease associated with

Sarah Lecordier1,2, Romain Menet1,2, Anne-Sophie Allain1,2

  • 1Neuroscience Axis, Research Center of CHU de Quebec - Université Laval, Quebec City, QC, Canada.

Insights

Non-classical CX3CR1 monocytes aid brain repair after cerebral small vessel disease (cSVD). Enhancing these cells reduced brain damage and improved cognitive function, offering a new therapeutic target for dementia.

Area of Science:

  • Neuroscience
  • Immunology
  • Vascular Biology

Background:

  • Cerebral small vessel disease (cSVD) is a primary cause of dementia.
  • Monocytes are implicated in cerebrovascular disorders.

Purpose of the Study:

  • To investigate the role of CX3CR1 monocytes in cSVD.
  • To explore CX3CR1 monocyte-based therapies for cSVD.

Main Methods:

  • Generated chimeric mice with functional or dysfunctional CX3CR1 monocytes.
  • Induced cSVD via micro-occlusion of cerebral arterioles.
  • Utilized immunomodulatory approaches targeting monocyte production.

Main Results:

  • Functional CX3CR1 monocytes infiltrated the hippocampus, correlating with reduced neuronal damage and blood-brain barrier disruption.
  • Dysfunctional monocytes led to worsened microinfarctions and cognitive decline.
  • Stimulating CX3CR1 monocyte generation improved cognitive function and vascular integrity.

Conclusions:

  • Non-classical CX3CR1 monocytes are crucial for neurovascular repair following cSVD.
  • Targeting CX3CR1 monocyte production presents a promising therapeutic strategy for cSVD-related dementia.